Welcome to our dedicated page for Evofem Bioscienc news (Ticker: EVFM), a resource for investors and traders seeking the latest updates and insights on Evofem Bioscienc stock.
Evofem Biosciences, Inc. (OTC: EVFM) regularly issues news and updates focused on women’s sexual and reproductive health, its FDA-approved products, and its corporate strategy. Company press releases highlight developments around PHEXXI, a hormone-free, on-demand prescription contraceptive vaginal gel, and SOLOSEC, a single-dose oral antimicrobial treatment for bacterial vaginosis and trichomoniasis.
News items cover a range of topics, including quarterly and annual financial results, cost-of-goods initiatives, and progress on international expansion. For example, Evofem has announced licensing arrangements with Pharma 1 Drug Store in the Middle East and North Africa, regulatory submissions for PHEXXI and SOLOSEC in the United Arab Emirates, and steps toward commercialization in Gulf Cooperation Council states. These updates provide context on how the company is seeking to diversify and expand its revenue stream beyond the United States.
Evofem’s releases also describe marketing and educational campaigns such as the "Say Vagina" initiative, which the company presents as an effort to normalize clinical language and address stigma around vaginal health. Other news has detailed the impact of social media campaigns on traffic to the PHEXXI website, engagement from healthcare providers, and broader brand awareness.
In addition, investors can find news about corporate actions and governance, including information on a previously proposed merger with Aditxt, Inc. and its subsequent termination, reverse stock split authorization, and capital raises through notes and warrants. This news page aggregates such announcements so readers can follow product, regulatory, commercial, and corporate developments related to Evofem Biosciences and its EVFM stock symbol over time.
Evofem Biosciences (Nasdaq: EVFM) announced the completion of the last subject's visit in its Phase 3 trial, EVOGUARD, for evaluating Phexxi as a preventive measure against chlamydia and gonorrhea in women. Top-line data is expected by October 2022, with a U.S. regulatory submission planned for the first half of 2023. If approved, Phexxi may become the first woman-controlled prophylactic against these STIs, complementing its current indication for pregnancy prevention. The FDA has granted Fast Track and Qualified Infectious Disease Product designations for the product.
Evofem Biosciences (Nasdaq: EVFM) praises the U.S. Department of Health and Human Services and other agencies for confirming that contraceptives must be covered without cost under the Affordable Care Act. CEO Saundra Pelletier emphasized the importance of this guidance in protecting access to contraception. The company plans to engage with insurers and pharmacy benefit managers to ensure compliance regarding its contraceptive product, Phexxi. Additionally, Evofem anticipates releasing results from its Phase 3 clinical trial evaluating Phexxi for preventing chlamydia and gonorrhea in women this fall.
Evofem Biosciences (Nasdaq: EVFM) will host a conference call on August 4, 2022, at 5:00 p.m. ET to discuss its second-quarter financial results and business highlights. Investors can join the call by dialing (800) 285-6670 for U.S. participants or (713) 481-1320 for international participants. The call will also be available via a live webcast at evofeminvestorroom.com. The company specializes in women's sexual and reproductive health, with Phexxi® as its first FDA-approved product, expected to report clinical trial data this fall.
Evofem Biosciences (Nasdaq: EVFM) has announced that its direct-to-consumer (DTC) campaign, House Rules, has won 12 healthcare and communications awards and is nominated for four more. The campaign, featuring Emmy-winning actress Annie Murphy, aims to raise awareness of Phexxi, a hormone-free contraceptive. To date, House Rules has increased brand awareness by 45%, reached 42 million video views, and resulted in over 33,000 telehealth exits. The campaign emphasizes women's choice in birth control, aligning with Evofem's mission to enhance women's reproductive health.
Evofem Biosciences, Inc. (Nasdaq: EVFM) announced a new educational birth control chart aimed at enhancing contraceptive counseling for healthcare providers in the U.S. This chart introduces twelve contraceptive methods, including the vaginal pH modulator, replacing outdated materials. The initiative reflects recent legal changes and aims to empower women in making informed decisions regarding contraception. Evofem's first product, Phexxi®, is a hormone-free contraceptive gel, with expectations to report Phase 3 clinical trial data for new indications in the fall.
Evofem Biosciences, Inc. (Nasdaq: EVFM) praised the U.S. House of Representatives for passing The Right to Contraception Act, which aims to ensure access to contraception. CEO Saundra Pelletier emphasized the need for women to have reliable and easy access to contraceptive options without interference from insurance companies. Evofem is known for its hormone-free contraceptive gel, Phexxi, and anticipates reporting Phase 3 trial data for new indications in fall 2022. The company develops innovative products for women's reproductive health.
Evofem Biosciences, Inc. (Nasdaq: EVFM) has partnered with a360 Media to increase awareness of its hormone-free contraceptive, Phexxi, through branded content in popular U.S. magazines and websites. The partnership is expected to reach a broad audience, particularly women aged 18-34, who make up 72% of Phexxi prescriptions. In the first two weeks of collaboration, new prescriptions for Phexxi rose by 16%. This initiative aims to promote Phexxi as a viable alternative to traditional contraceptive methods, enhancing visibility among potential users.
Evofem Biosciences (Nasdaq: EVFM) announced the publication of a peer-reviewed article in the Journal of Therapeutic Advances in Reproductive Health, detailing the mechanism of action of Phexxi®, a non-hormonal contraceptive. The article emphasizes Phexxi's role in maintaining vaginal pH to prevent pregnancy. Dr. Todd Chappell, lead author, highlighted its importance amid current contraceptive access discussions. This marks the second peer-reviewed publication on Phexxi in 2022, following data published in the Journal of Sexual Medicine earlier this year.
Evofem Biosciences (Nasdaq: EVFM) announced a Notice of Allowance from the USPTO for patent application 16/738,868, covering the composition of Phexxi® (lactic acid, citric acid, potassium bitartrate). This patent is expected to provide protection until at least 2033, consolidating Evofem's existing portfolio of over 40 patents. CEO Saundra Pelletier emphasized the significance of this patent in strengthening Phexxi's market potential, which offers women a hormone-free contraceptive option. The company aims to address unmet needs in women’s reproductive health.
Evofem Biosciences (Nasdaq: EVFM) has secured a significant agreement with a major pharmacy benefit manager (PBM) to enhance access to its hormone-free contraceptive Phexxi for millions of women. The deal removes prior authorization barriers, effective July 1, 2022, and is expected to save the company approximately $400,000 by the end of 2022 and close to $1 million annually. Evofem anticipates an increase in Phexxi prescriptions due to this broader access and is working to finalize similar agreements with additional payers.
FAQ
What is the current stock price of Evofem Bioscienc (EVFM)?
What is the market cap of Evofem Bioscienc (EVFM)?
